Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ISIS 301012 subcutaneous: Phase II data

In a Phase II trial in 48 patients already receiving high doses of lipid-lowering drugs, the 2 higher doses of ISIS 301012 met the

Read the full 249 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE